Anthera Pharmaceuticals (NASDAQ:ANTH) Earning Somewhat Positive Press Coverage, Accern Reports

News coverage about Anthera Pharmaceuticals (NASDAQ:ANTH) has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anthera Pharmaceuticals earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

ANTH has been the subject of a number of recent analyst reports. Jefferies Group LLC reaffirmed a “hold” rating and issued a $2.25 price objective on shares of Anthera Pharmaceuticals in a report on Monday, May 15th. Zacks Investment Research upgraded shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. Finally, ValuEngine cut shares of Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. Anthera Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $10.21.

Anthera Pharmaceuticals (NASDAQ:ANTH) traded up 1.92% on Friday, reaching $1.59. The company had a trading volume of 187,206 shares. The company’s 50 day moving average price is $1.66 and its 200-day moving average price is $1.06. Anthera Pharmaceuticals has a 12 month low of $1.47 and a 12 month high of $3.55. The company’s market capitalization is $16.02 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.47) by $0.56. On average, equities analysts predict that Anthera Pharmaceuticals will post ($5.06) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by BBNS and is the property of of BBNS. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/anthera-pharmaceuticals-nasdaqanth-earning-somewhat-favorable-press-coverage-analysis-finds-updated/1179821.html.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Insider Buying and Selling by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Chris Sale Reaches 200 Strikeouts in Record Time
Chris Sale Reaches 200 Strikeouts in Record Time
Veteran Pitcher Bartolo Colon Considering Retirement
Veteran Pitcher Bartolo Colon Considering Retirement
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana


Leave a Reply

 
© 2006-2017 BBNS.